Want to see SPRO full AI Analyst Report?
EarningsQ2 2026 Earnings Report
SPRO Q2 2026 EPS Results
Actual EPS-$0.16
Consensus EPS―
Beat/Miss―
One Year Ago EPS-$0.03
SPRO Q2 2026 Revenue Results
Actual Revenue$0.00
Expected Revenue―
Beat/Miss―
YoY Revenue Growth-100.00%
Earnings Announcement Details
QuarterQ2 2026
Date08/12/2026
TimeAfter Close
Conference CallWednesday, August 12, 2026
SPRO Upcoming Earnings
Spero Therapeutics's next earnings date is estimated for November 16, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
SPRO Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strategic positive shift: an important product approval (Utebzi), a high-value in-license (SP001) with a clear development plan in IgG4-RD, a non-dilutive $105M financing that extends runway into H2 2029, and a strengthened clinical leadership team. Offsetting these positives are an absence of current revenue (Q2 2026 revenue $0 vs $14.2M prior year), a wider net loss and increased loss per share, dependence on GSK royalty/milestone streams to service the financing, and SP001 remaining early-stage with a small planned Phase II. On balance, management’s actions materially de-risk near-term funding and position the company for an immunology strategy, but meaningful clinical and commercial execution risks remain.Company Guidance
FDA Approval of Utebzi (tebipenem pivoxil)
On June 17, 2026 the FDA approved Utebzi, the first and only oral carbapenem for complicated urinary tract infections (including pyelonephritis). Approval based on PIVOT-PO Phase III (stopped early for efficacy May 2025). GSK holds exclusive commercialization rights (excludes certain Asian territories where Meiji retains rights) and expects U.S. availability in the second half of 2026.
In-license of SP001 (IBI355) with Significant Upside
On July 8, 2026 Spero in-licensed SP001 from Innovent with an estimated total contingent deal value of $1.1 billion. Spero obtained exclusive worldwide rights excluding Greater China. SP001 is a third-generation Fc-silent IgG1 monoclonal antibody targeting CD40 ligand, has completed two Phase I studies and a Phase Ib in primary Sjogren's disease (data presented at EULAR June 2026). Spero plans a Phase II in IgG4-related disease expected to begin in Q2 2027 (open-label, two dosing arms, up to ~15 patients per arm).
Non-dilutive $105M Royalty Financing Strengthens Balance Sheet
Closed $105 million nondilutive, nonrecourse royalty financing with affiliates of Healthcare Royalty (KKR). Financing structured via a special purpose subsidiary issuing senior secured notes carrying 10% annual interest and a 9-year maturity; principal and interest payable quarterly and derived solely from GSK milestone and royalty payments on Utebzi. After repayment, Spero retains 35% of additional GSK milestone and royalty proceeds. Transaction provided immediate capital and extended cash runway guidance into the second half of 2029.
Cash Position and Runway Extension
Cash and cash equivalents were $50.8 million as of June 30, 2026 (does not reflect net proceeds from the $105M financing). Management expects the June 30 balance plus financing proceeds to fund the $35M nonrefundable upfront to Innovent and operations into the second half of 2029.
Leadership Hire — New Chief Medical Officer
Hired Dr. Debra Zack as Chief Medical Officer (joined August 3, 2026). Dr. Zack is a board-certified rheumatologist with a PhD in immunology and >25 years of clinical development leadership in immune-mediated diseases, strengthening clinical development capabilities for SP001 in immunology.
Reduced R&D Spend Year-over-Year
Research and development expense decreased to $3.4 million in Q2 2026 from $10.7 million in Q2 2025, a reduction of approximately 68.2%, primarily due to reduced clinical activity following early completion of the Phase III trial for Utebzi and lower personnel-related costs.
SPRO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed